NCT05744921: An ongoing trial by Regeneron Pharmaceuticals
This trial is ongoing. It must report results 3 years, 10 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05744921 |
|---|---|
| Title | An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 7, 2023 |
| Completion date | Feb. 26, 2029 |
| Required reporting date | Feb. 26, 2030, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |